TLR8 and ovarian carcinoma: Emerging evidence shows that TLR8 and its ligand act as suppressors in modulating mTOR-HIF-1α-induced glucose metabolism in intratumoral Tregs, and the TLR8 agonists Poly-G3 and ssRNA40 have been proven to be effective in disrupting Treg-mediated suppression of effector T cells in melanoma and ovarian cancer models [141, 143].